FDA recently announced that it had granted a first-ever approval of a combination treatment for melanoma

Login
Username

Password

Remember Me
/
Create an account

Name: (*)

Username: (*)

Password: (*)

Confirm Password: (*)

Email: (*)

Confirm email Address: (*)

Captcha: (*)

Fields marked with an asterisk (*) are required.

DERMASCOPE The authority on professional skin care

FDA recently announced that it had granted a first-ever approval of a combination treatment for melanoma

Written by Jeremy Lawrence

font size decrease font size increase font size
Print
Email

The United States Food and Drug Administration (FDA) recently announced that it had granted a first-ever approval of a combination treatment for melanoma, the most deadly type of skin cancer. The agency approved the combination of GlaxoSmithKline’s genetically-targeted dabrafenib (Tafinlar™) and trametinib (Mekinist™) for patients with metastatic or unresectable melanoma whose tumors possess either the BRAF V600E or V600K genetic mutations.